

# Chronic Hepatitis B Infection

## A Review


Lydia S. Y. Tang, MBChB; Emily Covert, BS; Eleanor Wilson, MD, MS; Shyam Kottlil, MD, PhD

**IMPORTANCE** More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer.

**OBSERVATIONS** Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis. Long-term viral suppression is associated with regression of liver fibrosis and reduced risk of hepatocellular carcinoma in cohort studies. The cure (defined as hepatitis B surface antigen loss with undetectable HBV DNA) rates after treatment remain low (3%-7% with pegylated interferon and 1%-12% with nucleos(t)ide analogue therapy). Pegylated interferon therapy can be completed in 48 weeks and is not associated with the development of resistance; however, its use is limited by poor tolerability and adverse effects such as bone marrow suppression and exacerbation of existing neuropsychiatric symptoms such as depression. Newer agents (entecavir, tenofovir disoproxil, and tenofovir alafenamide) may be associated with a significantly reduced risk of drug resistance compared with older agents (lamivudine and adefovir) and should be considered as the first-line treatment.

**CONCLUSIONS AND RELEVANCE** Antiviral treatment with either pegylated interferon or a nucleos(t)ide analogue (lamivudine, adefovir, entecavir, tenofovir disoproxil, or tenofovir alafenamide) should be offered to patients with chronic HBV infection and liver inflammation in an effort to reduce progression of liver disease. Nucleos(t)ide analogues should be considered as first-line therapy. Because cure rates are low, most patients will require therapy indefinitely.

JAMA. 2018;319(17):1802-1813. doi:10.1001/jama.2018.3795

 CME Quiz at  
[jamanetwork.com/learning](http://jamanetwork.com/learning)

**Author Affiliations:** Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore.

**Corresponding Author:** Shyam Kottlil, MD, PhD, Institute of Human Virology, University of Maryland, 725 W Lombard St, Room S222, Baltimore, MD 21201 ([skottlil@ihv.umaryland.edu](mailto:skottlil@ihv.umaryland.edu)).

**Section Editors:** Edward Livingston, MD, Deputy Editor, and Mary McGrae McDermott, MD, Senior Editor.

More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV).<sup>1</sup> Chronic HBV infection progresses to cirrhosis in up to 40% of untreated patients, and there is an associated risk of decompensated cirrhosis (defined as developing symptomatic complications of liver fibrosis such as jaundice, ascites, variceal hemorrhage, and hepatic encephalopathy) and hepatocellular carcinoma.<sup>2-5</sup> Research is ongoing regarding the relative efficacy of HBV treatments, their association with long-term outcomes, their relative safety and tolerability, and management strategies in special patient populations.

This review provides a summary of the current evidence regarding the treatment of patients with chronic HBV infection and summarizes clinical trial evidence regarding the efficacy of available antiviral treatments to improve outcomes, including preventing progression of liver fibrosis and hepatocellular carcinoma.

### Methods

We conducted a literature search of the PubMed, EMBASE, and the Cochrane databases for articles published from 1997 through

October 31, 2017. Results were limited to clinical trials of human adults with chronic HBV infection. Bibliographies of the retrieved studies and reviews were searched for other relevant studies. We also reviewed the reference articles that had been cited in the guidelines from the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver.<sup>2,6,7</sup>

### Epidemiology

Central and east Asia, sub-Saharan Africa, and the Pacific regions have the highest prevalence of HBV (range, 5%->8% of adults<sup>8</sup>), which is predominantly acquired during infancy or at a young age. Approximately 565 000 to 1 130 000 individuals in the United States (0.3%) have chronic HBV infection (Table 1).<sup>9-11</sup> However, higher levels of prevalence are observed in communities with large immigrant populations from countries with high levels of prevalence (Box 1),<sup>1</sup> and in communities with a large prevalence of individuals at high risk, including those who inject drugs, are incarcerated, and men who have sex with men (Table 2).<sup>12,13</sup>

There are 8 major HBV genotypes (A-H) in humans. In North America and Africa, the infections are primarily HBV genotype A

**Table 1. Major Epidemiological Characteristics of Patients With Chronic Hepatitis B Virus (HBV) Infection in the United States**

	Chronic HBV Infection From 1988-2012 (N = 565 000-1 130 000), <sup>a</sup> %
HBV genotype <sup>10</sup>	
A	35.0
B	22.0
C	31.0
D	10.0
Other	2.0
Race/ethnicity <sup>11,a</sup>	
Asian or Pacific Islander	27.9
White	13.3
Black	10.5
Hispanic	4.1
Non-Hispanic	3.4
Unknown	40.7
Sex <sup>11,a</sup>	
Male	54.7
Female	45.1
Age group, y <sup>11,a</sup>	
<25	6.7
25-39	33.7
40-54	32.4
≥55	27.3

<sup>a</sup> Category does not sum to 100% due to rounding.

(HBV genotype C is almost as common in the United States; Table 1), whereas infections in East Asia are most commonly HBV genotypes B and C and infections in Southern Europe and India are HBV genotype D. The HBV genotype A responds most favorably to interferon-based therapy relative to other genotypes,<sup>14</sup> and the HBV genotype C is associated with more advanced liver fibrosis and an increased risk of hepatocellular carcinoma.<sup>15,16</sup> Commercial testing for HBV genotype is not required for clinical care except when interferon-based therapy is considered, or when knowledge of the HBV genotype may aid risk stratification of disease progression.

### Life Cycle and Natural History of Chronic HBV Infection

The HBV virion and life cycle are illustrated in Figure 1. The HBV life cycle includes a phase that occurs within the hepatocyte nucleus in which HBV DNA is converted to a highly stable double-stranded circular DNA structure called covalently closed circular DNA. Hepatitis B virus DNA is also integrated into host DNA. Covalently closed circular DNA serves as a template for transcription of viral RNA, can persist indefinitely within the long-lived hepatocyte nucleus, and serves as a reservoir of viral replication.

The natural history of chronic HBV infection (which results from failure to clear acute infection) varies widely and is affected by host and viral factors. After acute HBV infection, infants are more susceptible to developing chronic HBV infection (90% of infants with acute infection develop chronic infection vs 5%-10% of adults).<sup>16</sup> Chronic HBV infection progresses to liver cirrhosis in up to 40% of untreated patients.<sup>2-4</sup> In an observational study<sup>4</sup> of 673 patients, 30% of patients with cirrhosis developed hepatocellular carcinoma during 10 years of follow-up.

### Box 1. Who Should be Screened for Chronic Hepatitis B Virus (HBV) Infection?<sup>a</sup>

- Individuals born in a country with at least moderate prevalence (ie, ≥2% of population is positive for HBV surface antigen [HBsAg])<sup>b</sup>
- Individuals with ≥1 parent from a country with high prevalence (ie, ≥8% of population is positive for HBsAg)<sup>b</sup>
- All pregnant women
- Household members and sexual partners of anyone infected with chronic HBV
- Individuals within the following groups are at an increased risk (≥2%) of HBV infection: those who are incarcerated, those who inject illicit drugs, men who have sex with men, those who have HIV, and those who have chronic hepatitis C virus infection (Table 2)
- Health care workers
- Patients undergoing immunosuppressive therapy (eg, chemotherapy, biological immunomodulators, after a transplant)
- Patients undergoing hemodialysis

Individuals meeting any of these criteria should be screened with serological tests for HBsAg, HBV surface antibody (anti-HBs), and HBV core antibody (anti-HBc). Such individuals also should have access to routine testing and care. If both HBsAg and anti-HBs are negative, then the HBV vaccine should be offered. Nonimmune pregnant women who are at risk of HBV infection (women who inject illicit drugs or who have sexual partners with HBV infection) should be vaccinated. Patients with chronic HBV infection are at risk of HBV reactivation and potentially life-threatening sequelae.

<sup>a</sup> Commercially available HBsAg screening tests have a sensitivity and specificity greater than 98%.

<sup>b</sup> All of Africa (>8% in most sub-Saharan and Western African countries), most of Asia except Japan (>8% in Mongolia, Vietnam, and Laos; >5% in China), Pacific Islands (>8%), New Zealand (>4%), Eastern Europe, Russia, Italy, Middle East (except Israel, Iran, Iraq, Lebanon), Ecuador and Peru, and the Caribbean (Haiti >8%).<sup>1</sup>

Chronic HBV infection accounts for at least 50% of hepatocellular carcinoma cases,<sup>17</sup> and primary liver cancer (approximately 75%-90% of cases are hepatocellular carcinoma) is the second most common cause of death from cancer in the world.<sup>18</sup> Among patients with HBV infection, hepatocellular carcinoma can develop in the absence of cirrhosis (approximately 10% of cases in a large Veteran's Affairs cohort of 8539 patients)<sup>19</sup>; however, hepatocellular carcinoma is typically preceded by cirrhosis (70%-90% of patients).<sup>5</sup>

### Diagnosis


Serological markers can be used to diagnose and distinguish between acute and chronic infections. Commercially available serological tests detect HBV surface antigen (HBsAg), HBV envelope antigen (HBeAg), HBV surface antibody (anti-HBs), HBV core antibody (anti-HBc), HBV envelope antibody (anti-HBe), and HBV DNA (Table 3).<sup>20</sup> Chronic HBV infection is defined as detection of HBsAg on 2 occasions measured at least 6 months apart.

Individuals at risk for HBV infection (populations with ≥2% prevalence of HBV infection) should be screened with serological tests for the presence of HBsAg, anti-HBs, and anti-HBc, and offered a vaccine if not immune (Box 1). Among individuals who recover from HBV infection, 80% will develop anti-HBs and all will develop anti-HBc.<sup>20</sup> Therefore, testing for anti-HBc is important for

Table 2. Patient Groups at Risk for Hepatitis B Virus (HBV) Infection <sup>12</sup>	
Group Description	Prevalence Range for HBV Infection, %
A household contact of an individual with chronic HBV	3.0-20.0
A sexual contact of an individual with chronic HBV	3.5-9.0
Individuals born outside the United States <sup>a</sup>	1.0-2.6
Individuals infected with HIV	4.0-17.0
Individuals who inject illicit drugs	2.7-11.0
Men who have sex with men	1.0-3.0
Individuals who are incarcerated <sup>13</sup>	0.3-3.1

<sup>a</sup> Additional information appears in Box 1.

Figure 1. The Hepatitis B Virion and Replication Cycle



The hepatitis B virion is a small enveloped DNA virus consisting of an outer lipoprotein envelope and an inner nucleocapsid core that houses the viral genome. The viral genome codes for all of the viral proteins required for replication: hepatitis B virus (HBV) surface antigen (HBsAg; 3 different sizes: small, medium, large), HBV core antigen (HBcAg), HBV envelope antigen (HBeAg), X protein, and HBV polymerase. The virus binds to the sodium taurocholate co-transporting polypeptide (NTCP) receptor on the surface of hepatocytes and is endocytosed, releasing its DNA-containing nucleocapsid into the cytoplasm where it is transported to the nucleus. In the nucleus, viral

DNA in its relaxed circular form is repaired and converted to closed covalent circular DNA (cccDNA). Integration of HBV DNA into the host genome also takes place. The cccDNA functions as a minichromosome and template for transcription of viral RNA. Due to the long half-life of hepatocytes, cccDNA will persist indefinitely within the host hepatocyte nucleus, thereby serving as a reservoir for reactivation of viral replication. Nucleos(t)ide analogues inhibit reverse transcription by HBV polymerase. mRNA indicates messenger RNA; L mRNA, large surface antigen mRNA; S mRNA, small and medium surface antigen mRNA; X mRNA, X protein mRNA.

identifying individuals who may have been previously infected (further described in Table 3). Individuals younger than 19 years should be vaccinated. Individuals in high-risk groups who were vac-

cinated as infants or schoolchildren should still be screened to determine immunity (or lack of) to HBV. Individuals with anti-HBs levels of less than 10 IU/L are considered not immune.



Table 3. Diagnosis of Acute and Chronic Hepatitis B Virus (HBV) Infection

Interpretation	HBsAg	Anti-HBs	Anti-HBc	HBV DNA Detected	Interpretation Details
HBV infection	Positive	Negative	Positive	Positive	<ul style="list-style-type: none"> <li>• Presence of HBsAg for &gt;6 mo defines chronic infection</li> <li>• In acute infection, anti-HBc is in the form of IgM</li> </ul>
Resolved infection	Negative	Positive	Positive	Negative	<ul style="list-style-type: none"> <li>• Adults infected with HBV will resolve infection within 6 mo</li> <li>• HBsAg is no longer detected (termed <i>HBsAg loss</i>)</li> <li>• 80% of adults will develop anti-HBs (termed <i>anti-HBs seroconversion</i>)<sup>20</sup></li> <li>• Anti-HBc is present in the form of IgG</li> </ul>
Immunity	Negative	Positive	Negative	Negative	<ul style="list-style-type: none"> <li>• Immunity gained through vaccination</li> </ul>
Isolated core	Negative	Negative	Positive	Negative or positive	<ul style="list-style-type: none"> <li>• Undetectable HBV DNA: previous infection without anti-HBs or level of anti-HBs is below the level of detection by serological test<sup>a</sup></li> <li>• Detectable HBV DNA: occult HBV infection<sup>a</sup></li> <li>• Period during acute infection either immediately after infection and before the appearance of HBsAg or during resolution of infection after HBsAg loss and before appearance of anti-HBs</li> <li>• False-positive test result</li> </ul>

Abbreviations: anti-HBc, HBV core antibody; anti-HBs, HBV surface antibody; HBsAg, HBV surface antigen.

<sup>a</sup> Individuals at risk for disease reactivation and should be identified prior to immunosuppressive therapy.

## Presentation

Individuals with chronic HBV infection are typically asymptomatic and are diagnosed during routine health maintenance or screening (eg, blood donation or an evaluation for an elevated level of liver enzymes). Among adults with acute HBV infection, only 5% to 10% will progress to chronic HBV infection. Only one-third of adults develop symptoms (eg, fever, fatigue, malaise, abdominal pain, jaundice) during an acute HBV infection. The remainder have subclinical or asymptomatic illness that may be undetected.<sup>21</sup>

## Phases of Chronic HBV Infection

Hepatitis B virus does not kill cells directly. Recognition of the virus as a foreign antigen activates the host immunity to target and destroy infected liver cells, resulting in inflammation and necrosis of liver tissue. However, this process occurs intermittently throughout the course of chronic HBV infection. A patient with chronic HBV infection can transition between periods (or phases) of immunologic activity and inactivity, possibly several times during a lifetime. Repeated periods of immunologic activity with associated liver injury leads to liver fibrosis and hepatocellular carcinoma (Figure 2).

Chronic HBV infection is divided into 4 phases: immunotolerance, HBeAg-positive immunoreactive disease, HBeAg-negative inactive disease (inactive chronic HBV or low replicative), and HBeAg-negative immunoreactive disease. These phases do not have unique clinical presentations. Individuals in the immunotolerance and HBeAg-negative inactive disease phases are asymptomatic and individuals in the HBeAg-positive immunoreactive and HBeAg-negative immunoreactive disease phases can range from asymptomatic to having liver failure. Therefore, serological markers are needed to determine disease phase.

The biomarkers used to determine the phase of chronic HBV infection consist of the presence or absence of HBeAg and anti-HBe, the quantity of HBV DNA (known as HBV DNA level), level of alanine aminotransferase (ALT; a sensitive marker of liver inflammation), and the presence or absence of intrahepatic necroinflammation and fibrosis. Combining these markers provides information about the presence of intrahepatic immunologic activity, which is a measure of damage to liver cells and is clinically important in determining the need for treatment initiation.

Figure 2 summarizes the serological and histological criteria in each phase of chronic HBV.<sup>6,7,16,18,22-26</sup> There are 2 immunologically active phases (the HBeAg-positive immunoreactive phase and the HBeAg-negative immunoreactive phase) and 2 immunologically inactive phases (the HBeAg-negative immunotolerance phase and the HBeAg-negative inactive phase).

Patients with acute HBV infection (infected perinatally or later in life) are positive for HBeAg. If chronic HBV infection develops over time, patients can become negative for HBeAg (which is termed *HBeAg loss*). This usually represents partial host immune control of the infection (ie, host mitigation of liver inflammation), and the patient transitions from HBeAg-positive to HBeAg-negative serostatus in most cases (67%-80%), which is associated with a decrease in HBV DNA level (<2000 IU/mL) and cessation of liver inflammation and injury (the HBeAg-negative inactive disease phase). The duration of each phase is not well described; however, by the fourth decade of life, most individuals with chronic HBV who were infected perinatally have undergone HBeAg loss and only 6% to 10% of adults aged 40 years or older remain positive for HBeAg.<sup>26</sup>


At any time during the course of chronic HBV infection, spontaneous, immunologic clearance of chronic HBV infection (defined as HBsAg loss with or without seroconversion to anti-HBs combined with an undetectable HBV DNA level in the peripheral blood) may occur. Immunologic clearance is associated with improved survival and reduced risk of liver failure and hepatocellular carcinoma<sup>27</sup> and occurs at an annual rate of 0.5% to 2% in the absence of treatment.<sup>16,28</sup>

## Key Concepts for HBV Cure

Three categories of cure have been defined: virological, functional (also referred to as immunologic cure), and partial. Virological cure is defined as eradication of HBV DNA from the blood and liver (with continued positive serological test results for anti-HBc with or without anti-HBs). Once hepatocytes are infected with HBV, a reservoir of covalently closed circular DNA is established in the nucleus of hepatocytes, contributing to the persistence of HBV infection (Figure 1).

Covalently closed circular DNA cannot be eradicated from liver cells; therefore, virological cure is unattainable and theoretical.

Figure 2. Phases of Chronic Hepatitis B Virus (HBV) Infection



Chronic HBV infection is divided into 4 phases. Patients transition between phases (ie, better and then worse or worse and then better). Not all patients will go through all of these phases. Some patients may transition through the phases rapidly such that distinct phases may not be discerned in clinical practice. Alternative nomenclature refers to phases of chronic HBV infection without intrahepatic inflammation and fibrosis as chronic infection, and those phases with intrahepatic inflammation and fibrosis as chronic hepatitis. Only 6% to 10% of adults older than 40 years who acquired chronic HBV

infection perinatally remain positive for HBeAg.<sup>26</sup> Anti-HBe indicates HBV envelope antibody; ALT, alanine aminotransferase.

<sup>a</sup> The upper limit of normal for ALT level was defined by the American Association for the Study of Liver Diseases as 19 IU/mL for women and 30 IU/mL for men.<sup>6</sup>

<sup>b</sup> The immunoreactive and immunoreactive phases may occur with ALT levels within 2 times the upper limit of normal.<sup>23</sup>

Functional cure is defined as HBsAg loss combined with undetectable levels of HBV DNA in the peripheral blood that is sustained indefinitely after a finite course of therapy. Partial cure is characterized by a low (<2000 IU/mL) to undetectable level of HBV DNA maintained indefinitely after treatment is stopped, but with detectable HBsAg.<sup>29</sup> Unlike virological cure, functional cure is attainable but occurs in only 3% to 11% of patients treated with interferon therapy.<sup>6,14,30-32</sup> HBeAg loss is associated with a decreased level of HBV DNA (termed *HBV DNA suppression*) and normalization of ALT level (indicative of reduced hepatic inflammation); therefore, partial cure is defined by HBeAg loss combined with a sustained low to undetectable level of HBV DNA and a normal ALT level.

The persistence of covalently closed circular DNA allows HBV infection to reactivate in individuals with previous functional cure (reversion to a detectable level of HBV DNA or HBsAg in a person who was previously negative for both) who are undergoing immunosuppressive therapy (eg, treatment with the B-cell-depleting che-

motherapy agent rituximab). The incidence of reactivation among patients who have immunologically cleared HBV (negative for HBsAg and positive for anti-HBc) ranges from 1.5% to 23.8%.<sup>33</sup>

The US Food and Drug Administration issued a warning regarding HBV reactivation in association with direct-acting antiviral agents during treatment for chronic hepatitis C virus that was based on 29 reported cases between November 2013 and October 2016.<sup>34</sup> However, a recent study<sup>35</sup> conducted from January 2014 through September 2016 of 62 290 veterans treated for chronic hepatitis C virus infection with direct-acting antiviral agents reported only 1 case of reactivation of resolved HBV infection.

## Evaluation of a Patient With Chronic HBV Infection

### Phase Assessment

Individuals with chronic HBV infection should be evaluated to determine the phase of infection and for the presence of liver inflammation and fibrosis (Figure 2). In addition to a comprehensive

**Box 2. Evaluation of a Patient With Chronic Hepatitis B Virus (HBV) Infection<sup>a</sup>****Laboratory Tests**

Quantitative HBV DNA

HBV envelope antigen (HBeAg) and HBV envelope antibody (anti-HBe)

Screening for HIV, hepatitis C virus, hepatitis A virus immunity

Complete blood cell count

Complete metabolic panel (glucose, electrolytes, assessment of renal and liver function, including measurement of liver enzyme level)

**Liver Fibrosis Evaluation**

Liver biopsy

Transient elastography

If either of the above is not available, a blood test should be used (types of blood tests include: FibroSure, FIB-4 [a score based on levels of aspartate aminotransferase {AST} and alanine aminotransferase and age], and APRI [AST-to-platelet ratio index])<sup>b</sup>

**Health Maintenance**

Hepatocellular carcinoma screening with ultrasonography, computed tomography, or magnetic resonance imaging

Hepatitis A vaccine

<sup>a</sup> Defined as 2 positive test results for HBV surface antigen measured at least 6 months apart.

<sup>b</sup> Cutoffs for advanced fibrosis (including cirrhosis based on FIB-4 and APRI scores) were originally validated among patients with chronic hepatitis C virus and HIV co-infection. The validity of the same cutoffs for patients with chronic HBV infection are unclear. In a study of 575 patients with chronic HBV infection who underwent a liver biopsy, increases in APRI and FIB-4 scores correlated with Ishak grade ( $P < .001$ ). However, the scores overlapped and an APRI score greater than 2.0 and an FIB-4 score greater than 3.25 missed advanced fibrosis or cirrhosis in 113 of 139 patients and 179 of 195 patients, respectively.<sup>36</sup> In a meta-analysis of FibroTest (name of the test in Europe; called FibroSure in the United States), there was a correlation with fibrosis diagnosis by METAVIR grade in 2494 patients, sensitivity for cirrhosis was 62% (95% CI, 47%-75%), and specificity was 91% (95% CI, 88%-93%).<sup>37</sup>

history and physical, the following blood tests should be obtained: HBV DNA level by quantitative polymerase chain reaction assay, complete metabolic panel, complete blood cell count, and serological testing for HBeAg and anti-HBe.

Because levels of ALT and HBV DNA fluctuate during the immunoactive phases, differentiating between these phases and the inactive chronic HBV phase requires serial measurements (at least every 3 months for  $\geq 1$  year). Additional items for consideration when evaluating a patient with chronic HBV infection appear in Box 2.<sup>36,37</sup>

**Liver Fibrosis Staging**

Liver biopsy remains the gold standard for establishing the presence of liver inflammation and fibrosis; however, a biopsy is associated with significant risks, including bleeding (0.60%)<sup>38</sup> and injury to other organs (0.08%),<sup>39</sup> and is subject to sampling error that can underestimate disease presence.<sup>40</sup> In 1 study,<sup>41</sup> 51 participants underwent 2 liver biopsies on the same day. Discordance (severe fibrosis in one sample but not the other) occurred in 12% of the participants.

Transient elastography, which is an imaging technique that uses vibration pressure waves to measure liver stiffness, can be used as a noninvasive alternative to liver biopsy.<sup>42</sup> If liver biopsy or transient elastography are not available or clinically feasible, proprietary composite biomarker scoring systems (FibroSure, aspartate aminotransferase [AST]-to-platelet ratio index [APRI], and FIB-4 [a score based on levels of AST and ALT and age]), which use biochemical markers to determine the likelihood of cirrhosis, can be used; however, the data regarding these scores and their correlation with Ishak and METAVIR liver pathology scores in chronic HBV infection are variable (Box 2).<sup>36,37,43</sup>

**Initiating Antiviral Treatment**

The therapeutic goals are to reduce the risk of liver failure and hepatocellular carcinoma. Treatment is indicated during the immunoactive phase of chronic HBV infection when liver injury and fibrosis occur. The immunoactive phase is when a patient has an ALT level greater than the upper limit of normal in combination with a high HBV DNA level ( $>2000$  IU/mL if negative for HBeAg or  $>20\,000$  IU/mL if positive for HBeAg), or if a patient has evidence of at least moderate liver inflammation or fibrosis. Patients with cirrhosis should be treated regardless of ALT level and at any detectable level of HBV DNA.

Furthermore, because a high level of HBV DNA is strongly associated with liver disease progression, treatment should also be offered to patients with HBV DNA levels greater than  $20\,000$  IU/mL and elevated ALT levels regardless of fibrosis stage. Clinical response to treatment is based on serological, biochemical, and virological responses (Box 3).

**Overview of the Available Therapies for the Treatment of Chronic HBV Infection**

There are 7 antiviral treatments for chronic HBV infection available in the United States, and the mechanisms of action and adverse effects appear in Table 4.<sup>2,7,14,31,32,44-62</sup> These antiviral treatments can be categorized into 2 groups: interferons and nucleos(t)ide analogues.

**Interferons**

**Mechanisms of Action and Adverse Effects |** Interferons (alfa, beta, and gamma) are cytokines that are endogenously produced by immune system cells in response to viral infections. All have antiviral and immunomodulatory effects; however, alfa and beta interferons have more potent antiviral actions. Injectable formulations of pegylated interferon alfa (pegylated interferon alfa-2a and alfa-2b) are available for HBV therapy.

The exact mechanism through which interferons have an antiviral effect is not understood, but it is believed to have both direct antiviral (degradation of covalently closed circular DNA and viral messenger RNA and inhibition of viral DNA) and host immunomodulation effects (boosting host immune response against infected hepatocytes, facilitating viral clearance).<sup>63,64</sup>

Pegylated interferon therapy is administered once weekly as a subcutaneous injection for 48 weeks. Its use is limited by adverse effects, which include cytopenia, exacerbations of neuropsychiatric symptoms such as depression and insomnia,<sup>14,32</sup> and induction of thyroid autoantibodies.<sup>65</sup> The frequency of adverse effects is summarized in Table 4.

**Box 3. Treatment Outcome Measures for Chronic Hepatitis B Virus (HBV) Infection<sup>a</sup>****Serological Response to Treatment****HBV surface antigen (HBsAg) loss**

The presence of HBsAg is a marker of persistent chronic infection. The HBsAg loss (undetectable HBsAg by commercially available assays) can be followed by the presence of HBV surface antibody (anti-HBs; known as anti-HBs seroconversion) and is associated with sustained undetectable levels of HBV DNA and improved prognosis. This is considered functional cure, but occurs at very low rates both on and off treatment.

**HBV envelope antigen (HBeAg) loss**

The role of HBeAg is not fully understood. However, detection of HBeAg (HBeAg-positive disease) is associated with increased replicative activity (HBV DNA levels can be >1 million IU/mL) and infectivity. Serological transition from HBeAg positive to negative is associated with reductions in liver inflammation and HBV DNA level. The HBeAg loss may be associated with detection of HBV envelope antibody (anti-HBe). It is not known whether production of anti-HBe is associated with improved prognosis.

**Virological Response to Treatment****HBV DNA suppression**

Inhibition of HBV DNA replication results in a reduction of HBV DNA level measured in blood. A reduction of HBV DNA level to below the level of local assay detection is the cornerstone of available antiviral treatment, especially the nucleos(t)ide analogues.

**Biochemical Response to Treatment****Alanine aminotransferase normalization**

Level of alanine aminotransferase is a surrogate marker of hepatic inflammation. Reduction to a normal level (termed *normalization*) is used to monitor response to treatment and is associated with improvement in liver inflammation and damage.

**Histological Response to Treatment****Liver biopsy**

Monitoring response to treatment via a liver biopsy is not routinely recommended in clinical practice.

<sup>a</sup> For patients symptomatic with liver failure, improvement in symptoms such as ascites and hepatic encephalopathy can be a measure of clinical response.

**Efficacy of Pegylated Interferon** | In randomized clinical trials, pegylated interferon achieved higher rates of HBeAg loss (30% vs 21% with lamivudine,  $P < .001$ ).<sup>31</sup> Long-term follow-up of patients treated with interferon has demonstrated an association between therapeutic response (with HBeAg loss and sustained HBV DNA suppression) and higher incidence of HBsAg loss,<sup>66</sup> improved liver histology,<sup>67</sup> and a reduction in cirrhosis and hepatocellular carcinoma compared with untreated controls.<sup>68</sup> However, overall responses remain suboptimal in that only approximately one-third of patients achieve HBeAg loss and fewer achieve HBsAg loss.

**Nucleos(t)ide Analogues**

**Adverse Effects** | The following 5 nucleos(t)ide analogues are available in the United States: lamivudine, adefovir, entecavir, tenofovir

disoproxil, and tenofovir alafenamide. The nucleos(t)ide analogues inhibit the RNA-dependent DNA polymerase reverse transcriptase.

Nucleos(t)ide analogues are oral medications taken once daily. These drugs have been well tolerated and adverse effects were generally mild to moderate in clinical trials. All nucleos(t)ide analogues carry a warning on their package inserts for lactic acidosis and severe hepatomegaly<sup>69-72</sup>; however, these adverse events were observed among patients taking the older nucleoside analogues such as stavudine and didanosine for HIV infection and these types of adverse events have not occurred in clinical trials for chronic HBV infection.

The most common adverse effects were fatigue (3.3%-10.4%), dizziness (5.0%-6.6%), headache (4.9%-15.5%), and nausea (3.0%-10.0%).<sup>51,58,61,73-75</sup> In trials of maternal-fetal transmission, there were no differences in fetal development and infant growth associated with nucleos(t)ide analogue therapy compared with no therapy.<sup>76,77</sup>

Tenofovir disoproxil is renally excreted. Due to its structural similarities with adefovir and cidofovir (both are known to cause clinically significant proximal tubule toxicity), there have been concerns for renal toxicity with its use (eg, Fanconi syndrome, diabetes insipidus, and bone demineralization). However, in phase 3 clinical trials<sup>78-80</sup> including 444 patients, Fanconi syndrome and diabetes insipidus were not reported after 144 to 240 weeks of treatment. One study of 280 patients<sup>78</sup> reported a mean decline in bone mineral density of 0.98% and 2.54% at the spine and hip after 240 weeks of treatment with tenofovir disoproxil. However, the fracture incidence was low (10 fractures among 7 patients) and was related to trauma, not use of the study drug.

The clinical significance of these bone density changes among patients taking tenofovir disoproxil is unclear and this drug has not been compared with placebo. Closer monitoring of renal function is warranted while patients are taking tenofovir disoproxil; however, there are no recommendations to increase bone density screening beyond age-appropriate preventive health recommendations. Similar to tenofovir disoproxil, tenofovir alafenamide is a prodrug of tenofovir, but has greater stability within plasma, resulting in higher levels of the active drug within liver cells, less systemic exposure, and less renal- and bone-related adverse effects compared with tenofovir disoproxil. This is consistent with short-term phase 3 studies, but long-term follow-up data are needed.

**Efficacy** | Lamivudine,<sup>46-50</sup> adefovir,<sup>53-55</sup> entecavir,<sup>81</sup> and tenofovir disoproxil<sup>82</sup> show histological improvement and reduce the level of HBV DNA in the blood in randomized trials of patients with HBeAg-positive and HBeAg-negative immunoinactive disease compared with placebo. After 1 year of treatment with lamivudine or adefovir, histological improvement was observed in 53% to 64% of patients compared with 23% to 33% of patients who received placebo ( $P < .001$  in all studies); and 60% of patients treated with adefovir for 1 year had HBV DNA levels below detection (compared with 0% in the placebo group).<sup>46,50,54,55</sup>

In a study by Liaw et al,<sup>48</sup> 651 patients were randomized to receive lamivudine or placebo. Treatment with lamivudine (median, 32 months) reduced the rate of overall liver disease progression among patients with advanced liver disease from 17.8% to 7.8% ( $P = .001$ ); furthermore, the incidence of hepatocellular carcinoma was less frequent with lamivudine compared with placebo (3.95%

Table 4. Mechanism of Action and Adverse Effects of Major Therapies Available for Chronic Hepatitis B Virus (HBV) Infection

Drug	Mode of Delivery and Dose	Mechanism of Action	Development of Resistance	Considerations for Use	Adverse Effects	Monitoring During Treatment	Efficacy
<b>Interferons</b>							
Pegylated alfa-2a Pegylated alfa-2b	Subcutaneous injection: 180 µg/wk for 48 wks	<ul style="list-style-type: none"> <li>Antiviral treatment that targets host</li> <li>Binds to type 1 interferon receptors, activating immunomodulatory and antiviral proteins</li> </ul>	No resistance reported	<ul style="list-style-type: none"> <li>Finite duration of therapy may be advantageous for women positive for HBeAg with high HBV DNA levels planning on getting pregnant</li> <li>Best treatment response seen among patients with HBV genotype A infection</li> </ul>	<ul style="list-style-type: none"> <li>Flu-like symptoms: fatigue or asthenia, pyrexia, myalgia, headache (30%-62%)<sup>14,31,32</sup></li> <li>Thyroid dysfunction (6%)<sup>44,45,a</sup></li> <li>Gastrointestinal symptoms: nausea, diarrhea, decreased appetite (9%-18%)<sup>4,31,32</sup></li> <li>Psychiatric disorders: depression (3%-21%),<sup>14,31,32</sup> insomnia (8%-15%)<sup>14,32</sup></li> <li>Dermatologic disorders: alopecia (14%-27%), pruritus (5%-14%)<sup>14,31,32</sup></li> <li>Neutropenia (17%-21%)<sup>14,32</sup></li> <li>Thrombocytopenia (13%-19%)<sup>14,32</sup></li> </ul>	<ul style="list-style-type: none"> <li>Liver function test and complete blood cell count at wks 2 and 4 and then monthly</li> <li>Measure thyroid stimulating hormone level every 12 wk</li> </ul>	HBV DNA and serological tests every 3 mo
<b>Nucleos(t)ide Analogues<sup>b</sup></b>							
Lamivudine	Oral: 100 mg/d	<ul style="list-style-type: none"> <li>Antiviral treatment that directly targets the virus</li> <li>Inhibits reverse transcriptase activity of HBV polymerase</li> </ul>	Resistance among 24%-30% after 1 y <sup>46,47</sup> and 70% after 5 y <sup>2,7</sup>		<ul style="list-style-type: none"> <li>Malaise or fatigue (15%-19%)<sup>46,48,49</sup></li> <li>Nausea, vomiting (9%)<sup>46,48,49</sup></li> <li>Headache (15%-17%)<sup>48-50</sup></li> <li>Upper respiratory tract infections (8%-35%)<sup>48-50</sup></li> <li>Abdominal pain (13%-15%)<sup>48-50</sup></li> <li>Diarrhea (14%)<sup>48,50</sup></li> </ul>	<ul style="list-style-type: none"> <li>Measure renal and liver function every 3-6 mo</li> <li>Assess lactic acid level<sup>c</sup></li> </ul>	HBV DNA and serological tests every 3-6 mo
Adefovir	Oral: 10 mg/d	<ul style="list-style-type: none"> <li>Antiviral treatment that directly targets the virus</li> <li>Inhibits reverse transcriptase activity of HBV polymerase</li> </ul>	Resistance among 20%-29% after 5 y <sup>51,52</sup>		<ul style="list-style-type: none"> <li>Headache (15%-24%)<sup>53,54</sup></li> <li>Abdominal pain (18%-24%)<sup>49,55</sup></li> <li>Nausea (10%)</li> <li>Asthenia (10%-25%)<sup>53-55</sup></li> </ul>	<ul style="list-style-type: none"> <li>Measure renal and liver function every 3-6 mo</li> <li>Assess lactic acid level<sup>c</sup></li> </ul>	HBV DNA and serological tests every 3-6 mo
Entecavir	Oral: 0.5-1.0 mg/d	<ul style="list-style-type: none"> <li>Antiviral treatment that directly targets the virus</li> <li>Inhibits reverse transcriptase activity of HBV polymerase</li> </ul>	<ul style="list-style-type: none"> <li>Resistance among 1.2% after 5 y in nucleos(t)ide-naïve patients</li> <li>Resistance increased to &gt;50% among patients with resistance to lamivudine<sup>56,57</sup></li> </ul>	Recommended as first-line therapy	<ul style="list-style-type: none"> <li>Headache (10%)<sup>61</sup></li> <li>Fatigue (6%)</li> <li>Elevated alanine aminotransferase level (4%-10%)<sup>58,59</sup></li> </ul>	<ul style="list-style-type: none"> <li>Measure renal and liver function every 3-6 mo</li> <li>Assess lactic acid level<sup>c</sup></li> </ul>	HBV DNA and serological tests every 3-6 mo
Tenofovir disoproxil	Oral: 300 mg/d	<ul style="list-style-type: none"> <li>Antiviral treatment that directly targets the virus</li> <li>Inhibits reverse transcriptase activity of HBV polymerase</li> </ul>	No resistance reported for up to 7 y <sup>60</sup>	Recommended as first-line therapy	<ul style="list-style-type: none"> <li>Headache (10%)<sup>61</sup></li> <li>Nasopharyngitis (10%)<sup>61,62</sup></li> <li>Nausea (9%)<sup>62</sup></li> <li>Fatigue (8%)<sup>62</sup></li> <li>Upper respiratory tract infection (7%)<sup>61</sup></li> </ul>	<ul style="list-style-type: none"> <li>Measure renal and liver function every 3-6 mo</li> <li>Assess lactic acid level<sup>c</sup></li> <li>Measure creatinine kinase level</li> <li>Category B drug for pregnancy</li> </ul>	HBV DNA and serological tests every 3-6 mo
Tenofovir alafenamide	Oral: 25 mg/d	<ul style="list-style-type: none"> <li>Antiviral treatment that directly targets the virus</li> <li>Inhibits reverse transcriptase activity of HBV polymerase</li> </ul>	No long-term follow-up data available	Recommended as first-line therapy	<ul style="list-style-type: none"> <li>Headache (14%)<sup>61</sup></li> <li>Nasopharyngitis (11%)<sup>61</sup></li> <li>Upper respiratory tract infection (7%)<sup>61</sup></li> <li>Fatigue (6%)<sup>61</sup></li> </ul>	<ul style="list-style-type: none"> <li>Measure renal and liver function every 3-6 mo</li> <li>Assess lactic acid level<sup>c</sup></li> <li>Category B drug for pregnancy</li> </ul>	HBV DNA and serological tests every 3-6 mo

Abbreviation: HBeAg, hepatitis B virus envelope antigen.

<sup>a</sup> Reported in observational studies but not in any randomized clinical trials.<sup>b</sup> Known as reverse transcriptase inhibitors. Most adverse events were graded as mild or moderate and not related to the drug; the frequency was similar in both intervention and comparison groups.<sup>c</sup> Lactic acidosis and severe hepatomegaly reported during postmarketing; all nucleos(t)ide analogues carry a black box warning.



vs 7.40%, respectively;  $P = .047$ ).<sup>48</sup> Treatment of patients with acute liver failure secondary to reactivation of chronic HBV infection with tenofovir disoproxil for up to 3 months was associated with an improvement in the probability of survival from 17% to 57% ( $P < .01$ ).<sup>82</sup> However, serological responses (HBeAg and HBsAg loss with or without detection of corresponding antibodies) were low (11%-32% and 0%-2%, respectively).<sup>47,49,53</sup>

Use of lamivudine and tenofovir disoproxil during pregnancy was associated with lower rates of HBV fetal transmission. In a study of 200 pregnant women who took tenofovir disoproxil during the third trimester, the rate of HBV transmission was reduced from 18% to 5% ( $P = .007$ ).<sup>76</sup>

**Drug Selection** | Lamivudine and adefovir were the first nucleos(t)ide analogues developed, and their use is limited by the development of resistant variants of HBV. In randomized clinical trials of lamivudine compared with placebo, mutant variants associated with reduced sensitivity to lamivudine were detected in approximately 30% of patients after just 1 year of treatment.<sup>46,47</sup> Mutations causing resistance to adefovir are detected in up to 20% to 29% of patients after 5 years of therapy.<sup>51,52</sup>

In contrast, more recently developed nucleos(t)ide analogues (entecavir and tenofovir disoproxil) have markedly lower rates of resistance with a 1.2% probability of developing a resistant strain after 5 years of entecavir therapy among patients not previously treated with nucleos(t)ide analogues<sup>56</sup> and no clinically significant resistant variants identified during up to 7 years of follow-up with tenofovir.<sup>60</sup> Cross-resistance occurs between lamivudine- and entecavir-resistant HBV strains, and the cumulative probability of developing entecavir-resistant variants is more than 50% among patients with disease refractory to lamivudine.<sup>56</sup>

Randomized clinical trials comparing entecavir or tenofovir disoproxil with either lamivudine or adefovir have demonstrated that entecavir and tenofovir disoproxil show histological improvement (including among patients with lamivudine-resistant HBV)<sup>59,83,84</sup> and HBV DNA suppression<sup>58,62,85</sup> more than the comparator. After 96 weeks of treatment with either entecavir or lamivudine, HBV DNA was suppressed in 80% of patients treated with entecavir compared with 39% treated with lamivudine ( $P < .001$ ).<sup>58</sup> The rate of HBV DNA suppression after 48 weeks of treatment with tenofovir disoproxil was 93% vs 63% with adefovir among patients positive for HBeAg ( $P < .001$ ) and was 76% vs 13%, respectively, among patients negative for HBeAg ( $P < .001$ ). However, the incidence of histological improvement was not different (approximately 70% for all).<sup>62</sup>

In randomized clinical trials comparing entecavir, tenofovir disoproxil, and tenofovir alafenamide, there was no difference in HBV DNA suppression and no therapy was associated with higher rates of HBeAg nor HBsAg loss (14%-30% and <1%, respectively).<sup>61,79,80,86</sup> Two randomized clinical trials compared tenofovir disoproxil and tenofovir alafenamide.<sup>61,80</sup> More than 90% of patients treated with either form of tenofovir achieved HBV DNA suppression; however, treatment with tenofovir alafenamide resulted in ALT level normalization more commonly than tenofovir disoproxil (50% vs 32%, respectively; between-group difference, 17.9% [95% CI, 8.0%-27.7%;  $P < .001$ ]) and the declines in the mean percentage for bone mineral density and renal function were lower with tenofovir alafenamide.

### Role of Combination Therapy

The combination of a pegylated interferon and a nucleos(t)ide analogue as initial therapy among untreated patients with viremia was evaluated in a randomized clinical trial of 740 patients.<sup>75</sup> Patients received pegylated interferon or tenofovir disoproxil either in combination or alone. The overall rates of HBsAg loss at 72 weeks (24 weeks after completion of interferon therapy) were low but significantly higher when pegylated interferon was combined with tenofovir compared with tenofovir alone (9.1% vs 0%, respectively;  $P < .001$ ) or pegylated interferon alone (2.8%;  $P < .005$ ).

However, when pegylated interferon was added to treatment for HBeAg-negative patients (total of 183 patients) already receiving nucleos(t)ide analogue therapy with an undetectable HBV DNA level, rates of HBsAg loss at 48 weeks of follow-up did not differ between individuals who received pegylated interferon and those who did not (7 of 93 patients [8%] with pegylated interferon combined with nucleos(t)ide analogue vs 3 of 90 patients [3%] with nucleos(t)ide analogue alone;  $P = .15$ ).<sup>75</sup>

The combination of entecavir and tenofovir disoproxil has been studied among patients who were not previously treated and among patients with HBV disease resistant to adefovir or entecavir. Antiviral efficacy of dual therapy did not differ from monotherapy and there was no meaningful between-group difference in HBsAg loss (0%-3%).<sup>87-89</sup>

### Selection of Antiviral Therapy

Selecting an antiviral regimen requires consideration of both host and viral factors. For most patients, treatment with a nucleos(t)ide analogue is optimal due to its excellent adverse effect profile and ease of administration.

The newer nucleos(t)ide analogues of entecavir, tenofovir disoproxil, and tenofovir alafenamide are considered first-line regimens because of their high efficacy and low rates of resistance. Treatment with an interferon is not associated with the development of mutant viruses with resistance to therapy; however, interferon therapy is not well tolerated.

Treatment with an interferon is contraindicated in patients with uncontrolled psychiatric disorders such as depression, autoimmune disease, severe cardiac disease, and cytopenia.<sup>65</sup> Treatment with an interferon should be reserved for patients with HBV genotype A and who are positive for HBeAg. Treatment with an interferon can also be considered in patients for whom a short-term treatment course is beneficial such as women planning to become pregnant.

### Long-Term Monitoring

All individuals with chronic HBV infection should be evaluated at least every 6 months for a history and physical, a complete metabolic panel with renal and liver function tests, complete blood cell counts, HBV DNA level, and serological tests for HBeAg and HBsAg. Patients with increasing HBV DNA and ALT levels should be evaluated more frequently.

### Screening for Hepatocellular Carcinoma

Hepatocellular carcinoma tumors double in volume every 4 to 6 months.<sup>90</sup> Therefore, ultrasonography of the liver should be performed every 6 months to screen for hepatocellular carcinoma in an adult patient even if ALT level is normal. In a randomized clinical

trial<sup>91</sup> of 18 816 patients, screening with ultrasonography of the liver and an alpha-fetoprotein test every 6 months was associated with earlier detection and improved hepatocellular carcinoma survival (5-year survival rate of 46.4% vs 0% among unscreened patients). There have been no randomized clinical trials comparing screening every 6 months with annual screening. An abnormal ultrasound of the liver should be followed up by either dynamic computed tomography or magnetic resonance imaging of the liver.<sup>92,93</sup>

## Controversies and Challenges

### Cessation of Nucleos(t)ide Analogue Therapy

The presence of HBsAg loss is associated with HBV DNA suppression and is an ideal outcome of antiviral therapy; however, this occurs in only 3% to 11% of patients treated with an interferon,<sup>6,14,30-32</sup> and in only 1% to 12% of patients treated with a nucleos(t)ide analogue for 5 to 7 years.<sup>60,94,95</sup> Therefore, most individuals initiated on nucleos(t)ide analogues remain on therapy indefinitely.

Recent observational studies have reported that the HBsAg loss and HBV DNA suppression that occur during antiviral therapy are durable even after treatment is stopped.<sup>96,97</sup> Therefore, stopping treatment can be considered after extending antiviral therapy 6 to 12 months after HBsAg and HBV DNA become undetectable. However, this approach has not been evaluated in a randomized clinical trial.

For patients without HBsAg loss, discontinuing therapy may be desirable due to potential long-term toxic effects, the cost of medication, and the development of resistance. Current recommendations allow consideration of therapy cessation 1 year after HBeAg becomes unmeasurable.<sup>2,6,7</sup> For patients who are negative for HBeAg

at the time of antiviral initiation, cessation can be considered after 3 years of therapy.<sup>2,7</sup>

High rates of virological relapse (91.4%) have been reported within 48 weeks of therapy cessation among patients with HBeAg-negative disease.<sup>57</sup> Patients with cirrhosis should remain on therapy at least until HBsAg loss regardless of HBeAg status; however, this recommendation is based on expert opinion, with few supporting data.

### Screening for Hepatocellular Carcinoma After HBsAg Loss

Even after HBsAg loss, hepatocellular carcinoma can occur, possibly related to persistent covalently closed circular DNA and integration of HBV into host DNA. In an observational prospective study<sup>98</sup> of 158 cases with HBsAg loss not receiving treatment (mean follow-up, 19.6 years), the annual incidence of hepatocellular carcinoma was 3.8%. There are few data to inform screening recommendations for patients without cirrhosis who undergo HBsAg loss (spontaneous or with antiviral therapy).

## Conclusions

Antiviral treatment with either pegylated interferon or a nucleos(t)ide analogue (lamivudine, adefovir, entecavir, tenofovir disoproxil, or tenofovir alafenamide) should be offered to patients with chronic HBV infection and liver inflammation in an effort to reduce progression of liver disease. Nucleos(t)ide analogues should be considered as first-line therapy. Because cure rates are low, most patients will require therapy indefinitely.

## ARTICLE INFORMATION

**Author Contributions:** Dr Kottitil had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Tang, Kottitil.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Tang, Covert, Kottitil.

**Critical revision of the manuscript for important intellectual content:** Tang, Wilson, Kottitil.

**Obtained funding:** Kottitil.

**Administrative, technical, or material support:** Covert, Kottitil.

**Study supervision:** Tang, Kottitil.

**Conflict of Interest Disclosures:** The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Tang, Wilson, and Kottitil reported receiving grant funding from Gilead Sciences. No other disclosures were reported.

**Submissions:** We encourage authors to submit papers for consideration as a Review. Please contact Edward Livingston, MD, at [Edward.livingston@jamanetwork.org](mailto:Edward.livingston@jamanetwork.org) or Mary McGrae McDermott, MD, at [mdm608@northwestern.edu](mailto:mdm608@northwestern.edu).

## REFERENCES

- Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection. *Lancet*. 2015;386(10003):1546-1555.

- Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B. *Hepatol Int*. 2016;10(1):1-98.
- Fattovich G. Natural history and prognosis of hepatitis B. *Semin Liver Dis*. 2003;23(1):47-58.
- Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance. *Eur J Gastroenterol Hepatol*. 2015;27(6):638-643.
- Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2011;9(1):64-70.
- Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology*. 2016;63(1):261-283.
- European Association for the Study of the Liver; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370-398.
- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection. *Vaccine*. 2012;30(12):2212-2219.
- Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in US households. *Hepatology*. 2016;63(2):388-397.
- Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States. *Gastroenterology*. 2003;125(2):444-451.

- Centers for Disease Control and Prevention. Chronic hepatitis B. <https://www.cdc.gov/hepatitis/statistics/2015surveillance/pdfs/2015HepSurveillanceRpt.pdf>. Accessed November 21, 2017.
- Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. *MMWR Recomm Rep*. 2008;57(RR-8):1-20.
- Kamarulzaman A, Reid SE, Schwitters A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. *Lancet*. 2016;388(10049):1115-1126.
- Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B. *Lancet*. 2005;365(9454):123-129.
- Wong GL, Chan HL, Yiu KK, et al. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2013;37(5):517-526.
- Chen CJ, Yang HI. Natural history of chronic hepatitis B revealed. *J Gastroenterol Hepatol*. 2011;26(4):628-638.
- Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer*. 2006;118(12):3030-3044.
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide. *Int J Cancer*. 2015;136(5):E359-E386.

19. Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. *J Hepatol*. 2017;66(2):355-362.
20. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. *Antivir Ther*. 2010;15(2):133-143.
21. Liang TJ. Hepatitis B: the virus and disease. *Hepatology*. 2009;49(5)(suppl):S13-S21.
22. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology*. 2002;35(6):1522-1527.
23. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. *Am J Med*. 2004;116(12):829-834.
24. Kumar M, Chauhan R, Gupta N, et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. *Gastroenterology*. 2009;136(4):1272-1280.
25. Liaw YF, Tai DI, Chu CM, et al. Acute exacerbation in chronic type B hepatitis. *Hepatology*. 1987;7(1):20-23.
26. Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus infection. *Clin Infect Dis*. 1993;16(5):709-713.
27. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. *J Hepatol*. 2005;42(2):188-194.
28. McMahon BJ. The natural history of chronic hepatitis B virus infection. *Hepatology*. 2009;49(5)(suppl):S45-S55.
29. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure. *Hepatology*. 2017;66(4):1296-1313.
30. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology*. 2008;135(2):459-467.
31. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2005;352(26):2682-2695.
32. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2004;351(12):1206-1217.
33. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. *J Clin Oncol*. 2013;31(22):2765-2772.
34. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus. *Ann Intern Med*. 2017;166(11):792-798.
35. Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. *Hepatology*. 2017;66(1):27-36.
36. Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. *J Hepatol*. 2016;64(4):773-780.
37. Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B. *Am J Gastroenterol*. 2014;109(6):796-809.
38. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. *Clin Gastroenterol Hepatol*. 2010;8(10):877-883.
39. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. *J Hepatol*. 1986;2(2):165-173.
40. ter Borg F, ten Kate FJ, Cuypers HT, et al. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. *J Clin Pathol*. 2000;53(7):541-548.
41. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology*. 2005;128(7):1898-1906.
42. Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis. *Aliment Pharmacol Ther*. 2016;43(4):458-469.
43. Li Y, Chen Y, Zhao Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis. *PLoS One*. 2014;9(8):e105728.
44. Koziellewicz D, Zalesna A, Dybowska D. Can pegylated interferon  $\alpha$  2a cause development of thyroid disorders in patients with chronic hepatitis B? *Expert Opin Drug Saf*. 2014;13(8):1009-1014.
45. Chen XF, Chen XP, Ma XJ, et al. Prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-alpha [in Chinese]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi*. 2012;26(2):117-119.
46. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med*. 1999;341(17):1256-1263.
47. Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B. *Antivir Ther*. 2007;12(3):345-353.
48. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351(15):1521-1531.
49. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. *Hepatology*. 1999;29(3):889-896.
50. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. *N Engl J Med*. 1998;339(2):61-68.
51. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *Hepatology*. 2008;48(3):750-758.
52. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology*. 2006;131(6):1743-1751.
53. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2005;352(26):2673-2681.
54. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med*. 2003;348(9):808-816.
55. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med*. 2003;348(9):800-807.
56. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology*. 2009;49(5):1503-1514.
57. Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B. *Gut*. 2015;64(4):667-672.
58. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. *Gastroenterology*. 2007;133(5):1437-1444.
59. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. *Gastroenterology*. 2006;130(7):2039-2049.
60. Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. *Dig Dis Sci*. 2015;60(5):1457-1464.
61. Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection. *Lancet Gastroenterol Hepatol*. 2016;1(3):196-206.
62. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med*. 2008;359(23):2442-2455.
63. Asselah T, Lada O, Moucari R, et al. Interferon therapy for chronic hepatitis B. *Clin Liver Dis*. 2007;11(4):839-849, viii.
64. Rijckborst V, Janssen HL. The role of interferon in hepatitis B therapy. *Curr Hepat Rep*. 2010;9(4):231-238.
65. US Food and Drug Administration. PEGASYS (peginterferon alfa-2a) package insert. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/103964s5154lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103964s5154lbl.pdf). Accessed June 20, 2017.
66. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology*. 2009;136(7):2169-2179.e1, 4.
67. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology*. 2004;39(3):804-810.
68. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. *J Hepatol*. 2007;46(1):45-52.
69. Gilead Sciences. VEMLIDY (tenofovir alafenamide) package insert. <https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease>

/vemlidy/vemlidy\_pi.pdf?la=en. Accessed June 20, 2017.

70. Gilead Sciences. VIREAD (tenofovir disoproxil fumarate) package insert. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/021356s042,022577s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021356s042,022577s002lbl.pdf). Accessed June 20, 2017.

71. Gilead Sciences. HEPSERA (adefovir dipivoxil) package insert. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/021449s020lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf). Accessed June 20, 2017.

72. Healthcare V. Epivir tablets and oral solution package insert. [https://www.viivhealthcare.com/media/32160/us\\_epivir.pdf](https://www.viivhealthcare.com/media/32160/us_epivir.pdf). Accessed June 20, 2017.

73. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy. *JAMA*. 2014;312(23):2521-2530.

74. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon  $\alpha$ -2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. *Gastroenterology*. 2016;150(1):134-144.e10.

75. Bourlière M, Rabiege P, Ganne-Carrie N, et al. Effect on HBs antigen clearance of addition of pegylated interferon  $\alpha$ -2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA. *Lancet Gastroenterol Hepatol*. 2017;2(3):177-188.

76. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. *N Engl J Med*. 2016;374(24):2324-2334.

77. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection. *J Viral Hepat*. 2009;16(2):94-103.

78. Fung S, Kwan P, Fabri M, et al. Tenofovir disoproxil fumarate (TDF) vs emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B. *J Hepatol*. 2017;66(1):11-18.

79. Sriprayoon T, Mahidol C, Ungtrakul T, et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients. *Hepatol Res*. 2017;47(3):E161-E168.

80. Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection. *Lancet Gastroenterol Hepatol*. 2016;1(3):185-195.

81. Tseng KC, Chen CY, Tsai HW, et al. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase. *Antivir Ther*. 2014;19(8):755-764.

82. Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. *Hepatology*. 2011;53(3):774-780.

83. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2006;354(10):1001-1010.

84. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2006;354(10):1011-1020.

85. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation. *Hepatology*. 2011;54(1):91-100.

86. Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients. *Hepatol Res*. 2018;48(1):59-68.

87. Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. *Gut*. 2016;65(6):1042-1051.

88. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. *Gastroenterology*. 2012;143(3):619-628.e1.

89. Lim YS, Byun KS, Yoo BC, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure. *Gut*. 2016;65(5):852-860.

90. An C, Choi YA, Choi D, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. *Clin Mol Hepatol*. 2015;21(3):279-286.

91. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2004;130(7):417-422.

92. Lin MT, Wang CC, Cheng YF, et al. Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. *PLoS One*. 2016;11(11):e0166157.

93. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma. *Hepatol Int*. 2017;11(4):317-370.

94. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology*. 2010;51(2):422-430.

95. Wong RJ, Nguyen MT, Trinh HN, et al. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients. *J Viral Hepat*. 2017;24(12):1089-1097.

96. Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B. *Gut*. 2014;63(8):1325-1332.

97. Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients [published online October 6, 2017]. *J Hepatol*. doi:10.1016/j.jhep.2017.09.018

98. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. *Hepatology*. 2010;51(5):1531-1537.